GHK-Cu
Also known as: Copper Peptide, Glycyl-L-histidyl-L-lysine copper complex, GHK-Cu2+
Overview
GHK-Cu is a naturally occurring tripeptide copper complex (glycyl-L-histidyl-L-lysine) first identified in human plasma in the 1970s. It functions as one of the most potent gene regulators among known peptides, influencing the activity of over 4,000 human genes. GHK-Cu levels decline by more than 60% between early adulthood and age 60, correlating with visible skin aging and reduced tissue repair capacity. It is extensively studied in dermatology, wound healing, and systemic anti-aging applications.
Mechanism of Action
GHK-Cu operates through multiple mechanisms: (1) gene regulation - large-scale profiling studies indicate modulation of 4,000+ genes, reactivating tissue repair genes while suppressing inflammatory and destructive pathways; (2) fibroblast stimulation - drives collagen, elastin, dermatan sulfate, and chondroitin sulfate synthesis; (3) MMP modulation - balances collagen remodeling through controlled metalloproteinase activity; (4) precision copper delivery - transports bioavailable copper to cells while suppressing free radical formation from ionic copper; (5) angiogenesis promotion; (6) anti-inflammatory activity reducing IL-6 and TNF-alpha.
Potential Benefits
- Statistically significant improvements in skin firmness and elasticity
- Reduction in fine lines and wrinkle depth over 3-6 months
- Accelerated wound healing and scar reduction
- Collagen and elastin production stimulation
- Improved skin density and moisture retention
- Hair follicle enlargement and growth stimulation
- Anti-inflammatory and antioxidant activity
- Gene expression 'reset' toward more youthful cellular programming
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Typical Range | 1-2 mg/day injectable; topical concentrations 0.1-2% |
| Beginner | 0.5-1 mg/day subcutaneously or topically |
| Intermediate | 1-2 mg/day subcutaneously |
| Advanced | 2-3 mg/day; combine injectable and topical formulations |
| Cycle Duration | 4-12 weeks injectable; topical can be used indefinitely |
| Cycle Off | 4-6 weeks off injectable; topical use can be continuous |
Injectable GHK-Cu is used for systemic anti-aging and wound healing. Topical formulations are well-established for skin rejuvenation and hair loss. Topical bioavailability enhanced with iontophoresis or microneedling.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High — systemic regenerative effects
Used for systemic anti-aging, wound healing, and tissue regeneration. Typical dose 1–3 mg daily.
Topical (Cream/Serum) Local skin effects — moderate dermal penetration
Most common consumer application. Used for skin rejuvenation, hair growth, and wound healing. Apply 1–2x daily to target area.
Intradermal (Microneedling) High local dermal delivery
Combined with microneedling for enhanced penetration. Popular in aesthetic medicine for collagen induction.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving GHK-Cu:
Skin Rejuvenation Stack
Anti-aging skin protocol. GHK-Cu promotes collagen synthesis and gene expression reset while Epitalon maintains telomere length. GHK-Cu topical + Epitalon injectable.
Wound Healing Stack
Comprehensive wound repair. GHK-Cu for collagen deposition and remodeling, BPC-157 for angiogenesis, TB-500 for cell migration and fibrosis reduction.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Typical Vial Size | 50mg/100mg (topical powder), 2mg/5mg (injectable) |
|---|---|
| BAC Water | 1-2ml per 2mg injectable vial |
| Storage | Refrigerate reconstituted injectable at 2-8°C; topical formulations at room temperature |
| Shelf Life | 28 days refrigerated (injectable); 6-12 months (topical formulations) |
Need exact syringe measurements?
Amino Acid Sequence
Gly-His-Lys (complexed with Cu2+ ion)
Side Effects & Safety
- Generally excellent topical safety profile
- Potential skin darkening with repeated use
- Rare allergic contact dermatitis
- Injection site reactions with parenteral use
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
FDA Safety Information
FDA Category 2 concerns (injectable): immunogenicity, limited human data.
Pharmacokinetics
| Half-Life | Minutes systemically; persistent local tissue effects from copper delivery |
|---|---|
| Storage | Store lyophilized at -20°C. Reconstituted/topical formulations refrigerated at 2-8°C. Protect from light. Avoid iron-containing vessels. |
Synergistic Compounds
The following compounds have been studied alongside GHK-Cu for potential complementary or synergistic effects:
Learn More
References & Further Reading
- GHK-Cu Complete Guide 2026 - Robertson Wellness
- GHK-Cu Skin Rejuvenation - Concierge MD
- GHK-Cu Anti-Aging Skincare - Infiniwell
- GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes
- The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.